Antifibrinolytic Therapy and Perioperative Considerations

Area of Science:

• Physiology
• Pharmacology
• Clinical Medicine

Background:

• Fibrinolysis is a critical part of hemostasis, regulating clot breakdown.
• Excessive fibrinolysis post-trauma or surgery can lead to coagulopathy and bleeding.
• Antifibrinolytic agents are vital for managing bleeding complications.

Purpose of the Study:

• To review the role of fibrinolysis in pathologic states.
• To examine pharmacologic agents that inhibit fibrinolysis.
• To focus on tranexamic acid's therapeutic efficacy in reducing surgical and trauma-related bleeding.

Main Methods:

• Literature review of fibrinolysis and antifibrinolytic agents.
• Analysis of clinical studies on tranexamic acid.
• Synthesis of data on bleeding reduction and clinical outcomes.

Main Results:

• Excessive fibrinolysis is a significant contributor to bleeding in trauma and surgical patients.
• Tranexamic acid is a well-studied and widely used antifibrinolytic agent.
• Evidence supports tranexamic acid's role in reducing blood loss and transfusions.

Conclusions:

• Inhibiting excessive fibrinolysis with agents like tranexamic acid is crucial for patient management.
• Tranexamic acid offers a valuable therapeutic option to mitigate bleeding risks.
• Further research may refine the application of antifibrinolytics in various clinical settings.